论文部分内容阅读
目的:评价三种给药方案治疗小儿支气管肺炎的成本-效果分析。方法:回顾性分析美洛西林、头孢呋辛、头孢哌酮/舒巴坦三种治疗小儿支气管肺炎给药方案的疗效及不良反应,并进行成本-效果分析。结果:A、B、C三组成本分别为1 486.60、1 601.46、1 737.65元;有效率分别为87.14%、97.22%、97.14%;成本-效果比分别为17.05、16.47、17.88;B、C组对于A组的增量成本-效果比分别为11.39、25.10。结论:与其他两种给药方案比较,头孢呋辛治疗小儿支气管肺炎疗效确切,符合药物经济学原理。
OBJECTIVE: To evaluate the cost-effectiveness analysis of three dosage regimens for the treatment of bronchial pneumonia in children. Methods: The curative effects and adverse reactions of mezlocillin, cefuroxime and cefoperazone / sulbactam in children with bronchopneumonia were retrospectively analyzed and the cost-effectiveness analysis was performed. Results: The costs of A, B and C were 1 486.60, 1 601.46 and 1 737.65 yuan, respectively. The effective rates were 87.14%, 97.22% and 97.14% respectively. The cost-effectiveness ratios were 17.05, 16.47 and 17.88, respectively. Group A for the incremental cost - effect ratio were 11.39,25.10. Conclusion: Compared with the other two dosage regimens, cefuroxime has an exact therapeutic effect on bronchopneumonia in children and is in line with the principles of pharmacoeconomics.